This inventor holds 1 USPTO granted patent. Top assignee: The General Hospital Corporation. Active years: 2018.
Company Filing History:
Years Active: 2018
Title: Martin Hertl: Innovator in Transgenic Research
Introduction
Martin Hertl is a notable inventor based in Gloucester, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of transgenic organisms. His work focuses on enhancing medical procedures through innovative genetic modifications.
Latest Patents
Hertl holds a patent for a groundbreaking invention titled "Miniature swine transgenic for one or more coagulation factors." This patent describes transgenic swine that express human coagulation factors, such as human coagulation factor VII, along with other factors like II, X, and XII. These swine do not express the corresponding porcine coagulation factors, making them valuable for medical research and transplantation procedures. The patent highlights the potential use of cells, tissues, and organs derived from these transgenic swine in various medical applications.
Career Highlights
Martin Hertl is associated with The General Hospital Corporation, where he continues to advance his research in transgenic technology. His work has implications for improving transplantation outcomes and understanding coagulation disorders. Hertl's innovative approach has positioned him as a key figure in the field of biomedical research.
Collaborations
Hertl collaborates with David H. Sachs, a prominent figure in transplantation research. Their partnership enhances the potential for breakthroughs in the application of transgenic technology in medicine.
Conclusion
Martin Hertl's contributions to transgenic research exemplify the intersection of innovation and biotechnology. His patent for transgenic swine represents a significant advancement in medical science, with the potential to improve transplantation procedures and patient outcomes.